Robert Scavo Sells 69,541 Shares of Alignment Healthcare (NASDAQ:ALHC) Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Robert Scavo sold 69,541 shares of the company’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $18.74, for a total value of $1,303,198.34. Following the transaction, the insider owned 503,014 shares of the company’s stock, valued at approximately $9,426,482.36. The trade was a 12.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alignment Healthcare Trading Up 2.7%

Shares of NASDAQ:ALHC opened at $19.75 on Thursday. Alignment Healthcare, Inc. has a fifty-two week low of $11.01 and a fifty-two week high of $21.06. The company has a quick ratio of 1.61, a current ratio of 1.61 and a debt-to-equity ratio of 1.99. The company has a market cap of $3.95 billion, a PE ratio of -164.58 and a beta of 1.16. The company’s 50-day moving average price is $18.26 and its 200 day moving average price is $16.24.

Alignment Healthcare (NASDAQ:ALHC) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03. The company had revenue of $993.70 million for the quarter, compared to analyst estimates of $980.90 million. Alignment Healthcare had a negative net margin of 0.57% and a negative return on equity of 16.23%. Alignment Healthcare’s revenue was up 43.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.14) earnings per share. Sell-side analysts anticipate that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current year.

Key Alignment Healthcare News

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Baird published a note saying Alignment “should be bought on recent selloff,” a catalyst that can draw value/income buyers and support the stock. Baird Buy Note
• Neutral Sentiment: Wall Street sentiment remains broadly constructive — several firms have Buy/Overweight ratings and the consensus target (~$20.35) sits near recent trade levels — which may limit downside if fundamentals stay intact. Analyst Coverage Summary
• Negative Sentiment: CEO John E. Kao sold 605,648 shares (~21.3% of his holding) at $18.74 for proceeds of about $11.35M — a large, high‑profile insider sale that can be interpreted negatively by investors. Kao SEC Filing
• Negative Sentiment: President Dawn Christine Maroney sold 282,070 shares (~16.9% of her holding) at $18.74 (~$5.29M), another sizable insider disposition that can weigh on sentiment. Maroney SEC Filing
• Negative Sentiment: Additional insider sales (Robert L. Scavo: 69,541 shares; Christopher J. Joyce: 16,187; Hyong Kim: 12,694) at the same $18.74 price add to the collective sell signal; combined insider disposals approach ~1M shares on Dec. 29–30. Scavo SEC Filing Joyce SEC Filing Kim SEC Filing

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Integrated Wealth Concepts LLC lifted its position in shares of Alignment Healthcare by 6.3% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 11,230 shares of the company’s stock valued at $196,000 after acquiring an additional 665 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of Alignment Healthcare by 2.3% in the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 37,752 shares of the company’s stock worth $659,000 after acquiring an additional 844 shares during the last quarter. Tidal Investments LLC raised its position in shares of Alignment Healthcare by 4.9% during the second quarter. Tidal Investments LLC now owns 18,094 shares of the company’s stock worth $253,000 after purchasing an additional 852 shares during the period. Jefferies Financial Group Inc. raised its position in shares of Alignment Healthcare by 4.3% during the third quarter. Jefferies Financial Group Inc. now owns 24,359 shares of the company’s stock worth $425,000 after purchasing an additional 1,014 shares during the period. Finally, Ballentine Partners LLC lifted its holdings in shares of Alignment Healthcare by 10.2% during the second quarter. Ballentine Partners LLC now owns 12,862 shares of the company’s stock valued at $180,000 after purchasing an additional 1,188 shares during the last quarter. Institutional investors and hedge funds own 86.19% of the company’s stock.

Analyst Upgrades and Downgrades

ALHC has been the subject of a number of analyst reports. KeyCorp reiterated an “overweight” rating on shares of Alignment Healthcare in a research report on Monday, November 24th. Barclays upped their price objective on shares of Alignment Healthcare from $13.00 to $18.00 and gave the stock an “equal weight” rating in a report on Friday, October 31st. JPMorgan Chase & Co. increased their target price on shares of Alignment Healthcare from $20.00 to $23.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Wall Street Zen upgraded shares of Alignment Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, Zacks Research lowered shares of Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.35.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.